证券代码：301156 证券简称：美农生物 公告编号：2026-001 上海美农生物科技股份有限公司 关于变更持续督导保荐代表人的公告 证券代码：301156 证券简称：美农生物 公告编号：2026-001 中泰证券作为公司首次公开发行股票并在创业板上市项目的保荐机构，持续 督导期为 2022 年 6 月 17 日至 2025 年 12 月 31 日。鉴于公司首次公开发行股票 的募集资金尚未使用完毕，根据中国证券监督管理委员会和深圳证券交易所相关 规定，中泰证券仍需对公司募集资金的管理和使用情况继续履行持续督导职责。 中泰证券原指定嵇志瑶女士、陶雪祺先生为该项目的签字保荐代表人。现陶雪祺 先生因工作变动，不再负责美农生物持续督导工作。为保证持续督导工作的顺利 进行，中泰证券决定授权马骏王先生（简历详见附件）接替陶雪祺先生担任该项 目持续督导的保荐代表人，继续履行持续督导职责。 本次变更后，公司首次公开发行股票并在创业板上市项目的持续督导保荐代 表人为嵇志瑶女士、马骏王先生，持续督导期限直至中国证券监督管理委员会和 深圳证券交易所规定的持续督导义务结束为止。 公司董事会对陶雪祺先生在担任公司持续督导保荐代表人期 ...

Core Viewpoint - The company has successfully completed various inspections and obtained necessary permits for its corn protein processing project, which is expected to enhance production capacity and competitive advantage in the domestic feed enzyme protein sector, positively impacting revenue growth and operational quality [1] Group 1 - The company announced that its "annual production capacity of 100,000 tons of corn protein processing project" has completed fire acceptance, safety simultaneous acceptance, and completion acceptance [1] - The company has obtained pollution discharge permits for the project [1] - The wholly-owned subsidiary, Leiling Meinong, received a "Feed Production License" from the Shandong Provincial Animal Husbandry and Veterinary Bureau [1] Group 2 - The project is expected to expand the company's production scale [1] - The project will strengthen the company's competitive advantage in the domestic feed enzyme protein field [1] - The launch of related products is anticipated to have a positive impact on the company's revenue growth and operational quality [1]

Core Viewpoint - Meino Bio (301156.SZ) has made significant progress in its "annual production of 100,000 tons of corn protein deep processing project" by completing various inspections and obtaining necessary permits, which is expected to enhance its competitive advantage in the domestic feed enzymatic protein sector and positively impact revenue growth and operational quality [1][1][1] Group 1 - The company has completed fire acceptance, safety simultaneous acceptance, and completion acceptance for its corn protein project [1] - The company has obtained a pollution discharge permit, marking a critical milestone for the project [1] - The subsidiary, Leiling Meino, has received a feed production license from the Shandong Provincial Animal Husbandry and Veterinary Bureau [1] Group 2 - The project is expected to expand the company's production scale and strengthen its competitive position in the feed enzymatic protein market [1] - The investment aligns with the company's overall strategic planning and supports long-term high-quality development [1] - The investment does not harm the interests of the company or its shareholders, particularly minority shareholders [1]

证券代码：301156 证券简称：美农生物 公告编号：2025-068 上海美农生物科技股份有限公司 关于投资建设年产 10 万吨的玉米蛋白精加工项目进展 暨取得生产许可证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资概述 上海美农生物科技股份有限公司（以下简称"公司"）第五届董事会第七次 会议审议通过了《关于对外投资项目的议案》，第五届董事会第九次会议及公司 2024 年第三次临时股东大会审议通过了《关于变更部分募集资金用途、使用部 分募投项目节余资金和超募资金用于投资 10 万吨玉米蛋白精加工项目的议案》， 同意公司设立全资子公司美农生物科技（乐陵）有限公司（以下简称"乐陵美农"） 投资建设"年产 10 万吨的玉米蛋白精加工项目"，并变更部分募集资金用途、 使用部分募投项目节余资金和超募资金用于投资该项目，项目计划投资约 3.91 亿元人民币。董事会授权公司管理层及其授权人士办理相应投资审批备案手续、 签署与本项目相关各类协议、设立子公司等事项。授权期限自公司董事会审议通 过之日起至相关授权事项办理完毕之日止。具体内容详见公司在巨潮资 ...

Core Viewpoint - Shanghai Quanyu Zhihhe Management Consulting Firm (Limited Partnership), a shareholder of Meino Bio (301156.SZ), plans to reduce its holdings by up to 1,407,846 shares, representing no more than 1% of the company's total share capital, within three months after the announcement [1] Group 1 - Quanyu currently holds 8,985,619 shares, accounting for 6.38% of the company's total share capital [1] - The reduction is due to funding needs of some partners within Quanyu [1] - Key individuals, including the actual controller and vice general manager Wang Jihong, as well as director Xiao Weiwei, will not participate in this reduction plan or share in the proceeds from the share reduction [1]

今日焦点 紫金矿业：2025年净利润同比预增59%—62% 紫金矿业公告称，紫金矿业预计2025年度归属于上市公司股东的净利润约510亿元-520亿元，同比增加 约59%-62%。报告期内，主要矿产品产量同比增长，其中矿产金、矿产铜、矿产银产量及销售价格上 升，当量碳酸锂产量大幅增长，推动公司盈利显著提升。 天普股份：8月22日至12月30日累计上涨718.39% 股票明起停牌核查 天普股份公告称，鉴于近期公司股票价格短期波动较大，且公司股价累计涨幅较大，自8月22日至12月 30日累计上涨718.39%，期间已累积巨大交易风险，现已严重偏离上市公司基本面，为进一步维护投资 者利益，公司就近期股票交易情况进行停牌核查。经向上海证券交易所申请，公司股票将于2025年12月 31日（星期三）开市起停牌，自披露核查公告后复牌。公司无开展人工智能相关业务的计划，与股东中 昊芯英未签订任何框架性合作协议。中昊芯英自身现有资本证券化路径与上市公司无关，无资产注入计 划。 盐湖股份：拟46.05亿元现金收购五矿盐湖51%股权 明德生物公告称，公司与蓝帆医疗签署《股权收购意向协议》，拟以现金方式收购武汉必凯尔救助用品 有限公 ...

Group 1: Share Buybacks - Zhongju Gaoxin plans to repurchase shares worth between 300 million to 600 million yuan for cancellation and reduction of registered capital [3] - Baili Tianheng intends to buy back shares valued at 100 million to 200 million yuan, with a maximum price of 546 yuan per share [3] - Guangqi Technology aims to repurchase shares worth 50 million to 100 million yuan [3] - Proya plans to buy back shares valued at 80 million to 150 million yuan [3] Group 2: Share Reductions - Jiangbolong's senior management has completed the share reduction plan [3] - Hengda New Materials' shareholder Longyou Lianlong plans to reduce its stake by no more than 3% [3] - Guosen Securities' shareholder FAW Investment has reduced its holdings by 22 million shares, completing the reduction plan [3] - United Precision's controlling shareholder He Guijing has cumulatively reduced 319,000 shares from December 29 to 30 [3] - Gu Zhong Technology's senior management Zhou Xiaoqing plans to reduce no more than 0.01% of shares [3] - Huaxing Yuanchuang plans to reduce no more than 434,900 shares already repurchased [3] - Su Shi Testing's controlling shareholder Su Shi General Factory intends to reduce no more than 2% of shares [3] - Chaojie Co. has completed the reduction of 3,985,500 shares [3] - Hongxun Technology's shareholder Bangbangmang plans to reduce no more than 3% of shares [3] - Leiguang Co.'s Xinda Securities has reduced 14.3 million shares, bringing its holding below 5% [3] - Ruihua Tai's shareholder Guotou Gaoke plans to reduce no more than 1% of shares [3] - Meinong Biological's shareholder Quanyu plans to reduce no more than 1% of shares [3] - Youbuxun's controlling shareholder and its concerted parties plan to reduce a total of no more than 2.96% of shares [3] - Wuzhou Xinchun's third-largest shareholder Wuzhou Holdings reduced 10 million shares from November 3 to December 29 [3]

Group 1: Share Buybacks - Zhongju Gaoxin plans to repurchase shares worth between 300 million to 600 million yuan for cancellation and reduction of registered capital [2] - Baili Tianheng intends to repurchase shares for 100 million to 200 million yuan, with a maximum price of 546 yuan per share [2] - Guangqi Technology aims to repurchase shares worth 50 million to 100 million yuan [2] - Proya plans to repurchase shares for 80 million to 150 million yuan [2] Group 2: Share Reductions - Jiangbolong's senior management has completed the share reduction plan [2] - Hengda New Materials' shareholder Longyou Lianlong plans to reduce no more than 3% of the company's shares [2] - Guoxin Securities' shareholder FAW Investment has completed the reduction of 22 million shares [2] - United Precision's controlling shareholder He Guijing reduced 319,000 shares from December 29 to 30 [2] - Su Shiyan's controlling shareholder plans to reduce no more than 2% of shares [2] - Ziguang shares saw a reduction of 14.3 million shares by Cinda Securities, dropping its holding below 5% [2]

Core Viewpoint - The company announced that its shareholder, Shanghai Quanyu Zhihhe Management Consulting Firm (Limited Partnership), plans to reduce its holdings by up to 1,407,846 shares, representing 1% of the total share capital, within three months after the announcement [1] Summary by Relevant Sections - **Shareholder Information** - Shanghai Quanyu holds 8,985,619 shares, accounting for 6.38% of the company's total share capital [1] - **Reduction Plan** - The planned reduction will occur through centralized bidding and will not exceed 1,407,846 shares [1] - **Involvement of Key Personnel** - The actual controller, Wang Jihong, and director, Xiao Weiwei, will not participate in this reduction plan or share in the proceeds from the share reduction [1]

Core Viewpoint - Shanghai Quanyu Zhihhe Management Consulting (Limited Partnership), a shareholder holding 6.38% of Meino Bio (301156), plans to reduce its stake by up to 1% of the total share capital through centralized bidding within three months after 15 trading days [1] Group 1 - The shareholder intends to sell no more than 1,407,800 shares of Meino Bio [1]